301246 Hubei Hongyuan Pharmaceutical Technology
- 16.30
- +0.18+1.12%
Hubei Hongyuan Pharmaceutical Technology News
Hongyuan Pharmaceutical (301246.SZ): Net profit of 31.991 million yuan in the first quarter decreased by 51.81% year-on-year
Gelonghui, April 22 | Hongyuan Pharmaceutical (301246.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 426 million yuan, down 15.45% year on year; net profit attributable to shareholders of listed companies was 31.991 million yuan, down 51.81% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 19.06.38 million yuan, down 62.26% year on year; basic earnings per share were 0.0780 yuan.
Express News | Since April, nearly 10 listed companies have announced illegal short-term transactions involving senior directors and supervisors
Hongyuan Pharmaceutical (301246.SZ): Initial repurchase of 110,000 shares involving 1.960.99 million yuan
Gelonghui, April 8, 丨 Hongyuan Pharmaceutical (301246.SZ) announced that on April 3, 2024, the company repurchased shares through centralized bidding transactions for the first time through a special stock repurchase securities account. The number of shares repurchased was 110,000 shares, accounting for 0.0275% of the company's current total share capital. The highest transaction price for the repurchase was 17.92 yuan/share, the minimum transaction price was 17.79 yuan/share, and the total transaction amount was 19.09.85 million yuan (excluding transaction fees).
Hongyuan Pharmaceutical (301246.SZ): Currently, the lithium battery materials industry is experiencing phased overcapacity
Gelonghui, April 8 | Hongyuan Pharmaceutical (301246.SZ) said on the investor interactive platform that the lithium battery materials industry is currently experiencing phased overcapacity, but the lithium battery industry will maintain a relatively rapid growth rate in the long run. In the future, the company will continue to enhance the competitiveness of the company's lithium hexafluorophosphate business through technological iterative upgrading and expansion upstream of the industrial chain. At the same time, it will lay out products such as additives and functional lithium salts, form industrial collaboration with the lithium hexafluorophosphate business, and continue to enhance the business scale and market competitiveness of the company's lithium battery sector. The company strictly complies with regulatory requirements and laws and regulations to fulfill its information disclosure obligations, and the company will pass
Hongyuan Pharmaceutical (301246.SZ): Repurchase has not been implemented
Gelonghui, April 2, 丨 Hongyuan Pharmaceutical (301246.SZ) announced that as of March 31, 2024, the company's special securities account had not implemented operations related to this share repurchase.
Hongyuan Pharmaceutical (301246.SZ): Lithium hexafluorophosphate, one of the main materials for the production of lithium battery electrolytes, has a business cooperation with BYD
Gelonghui March 26 丨 Some investors asked Hongyuan Pharmaceutical (301246.SZ) on the investor interactive platform, “Does the company cooperate with BYD, Xiaomi, Tesla, etc. regarding batteries? Is the company considering entering the robot battery industry?” The company replied that lithium hexafluorophosphate, one of the main materials for lithium battery electrolytes, has business cooperation with BYD. Please pay attention to the company's subsequent announcements for future investments in the field of new energy batteries.
A-share changes丨Hongyuan Pharmaceutical plummeted by more than 13% and 112 million restricted shares were lifted today
Gelonghui, March 20 | Affected by the lifting of the share ban, Hongyuan Pharmaceutical (301246.SZ) plummeted by more than 13% at the beginning of the session. The decline temporarily ranked first in the market. The stock price fell below the 20 yuan mark, with a total market value of 7.8 billion yuan. According to news, the company lifted the listing ban on 112 million restricted shares today, making it the company's initial shareholder's restricted shares, accounting for 27.94% of the company's total share capital. After the ban was lifted, the company still has 252 million restricted shares, accounting for 62.88% of the total share capital.
Zhitong A Share Sale Restriction and Release List | March 20
According to the Zhitong Finance App, the ban on restricted shares of 7 listed companies was lifted on March 20, with a total market value of about 4.575 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Aerospace Rainbow 002389, share incentives, 262.62, 10,000 Huachangda 300278 additional A-shares, corporate placement and listing 72 million, Hongyuan Pharmaceutical 301,246 pre-issuance shares limited sale and circulation 112 million, Chongde Technology 301548 A shares issuer, corporate placement and listing 7774 million Tongda Hai 301,378 shares before issuance
Hongyuan Pharmaceutical (301246.SZ): The ban on 112 million restricted shares will be lifted on March 20
Gelonghui March 18 丨 Hongyuan Pharmaceutical (301246.SZ) announced an indicative announcement regarding the listing and circulation of some shares issued prior to the initial public offering. The restricted shares currently listed in circulation are some shares already issued before the initial public offering. The total number of shareholders applying to lift the sales restrictions is 710. The number of restricted shares is 112 million shares, accounting for 27.94% of the company's total share capital after issuance. The sales restriction period is 12 months from the date of listing of the company's shares; the listing and circulation date of the shares lifted is March 20, 2024 (Wednesday).
Hongyuan Pharmaceutical (301246.SZ) plans to repurchase 1.6 million shares to 3.2 million shares, the repurchase price will not exceed 31 yuan/share
Hongyuan Pharmaceutical (301246.SZ) announced that the company plans to use its own funds to repurchase the company's shares through centralized bidding,...
Express News | Hongyuan Pharmaceutical: Proposed repurchase of no more than RMB 99.2 million
Hongyuan Pharmaceutical (301246.SZ) issued a pre-cut. The net profit for 2023 is expected to be 83 million yuan to 97 million yuan, a sharp drop of 77.69% to 80.91%
Hongyuan Pharmaceutical (301246.SZ) disclosed its 2023 annual results forecast. The company is expected to be a shareholder of a listed company...
Hongyuan Pharmaceutical (301246.SZ) released the first three quarter results, net profit of 96.3002 million yuan, a decrease of 74.15%
Hongyuan Pharmaceutical (301246.SZ) released its report for the third quarter of 2023. The company's revenue for the first three quarters was 1...
Hongyuan Pharmaceutical (301246.SZ): The company currently does not sell diet drugs or cancer-targeted drugs
Glonghui, Oct. 18丨Hongyuan Pharmaceutical (301246.SZ) said on the investor interactive platform that the company currently does not sell diet drugs or cancer-targeted drugs.
[Instant Analysis of BT Financial Report] Hongyuan Pharmaceutical's 2023 Interim Report: Net profit declined, balance ratio improved significantly
Hongyuan Pharmaceutical (stock code: 301246) is a high-tech enterprise specializing in pharmaceuticals and lithium battery materials. The company has established a complete industrial chain in the pharmaceutical field, covering the production of nitroimidazole-like antimicrobials, anti-herpesvirus drugs, and penicillin-like antimicrobials. In addition, the company also produces lithium hexafluorophosphate, one of the main materials for lithium battery electrolytes. However, the decline in the company's net profit in the most recent financial report was mainly affected by the lithium hexafluorophosphate business. According to Hongyuan Pharmaceutical's 2023 interim report, the company's total assets at the end of the period were 5.71 billion yuan, an increase of 47.38 billion yuan over 3.874 billion yuan at the beginning of the period
Changes in A-shares 丨 Hongyuan Pharmaceutical fell nearly 5% to reach a record low and the ban on shares was lifted
Gelonghui September 20 | Hongyuan Pharmaceutical (301246.SZ) fell nearly 5%, and its stock price fell below the 30 yuan mark. The low was 28.5 yuan, creating a new low listing price, with a total market value of 11.5 billion yuan. According to the news, the listing of 2,885,500 restricted shares of the company was lifted today, placing shares for the company's initial issuing agency, accounting for 0.72% of the company's total share capital. Furthermore, diet pills are popular recently, and the company recently claimed that the invention patent for “a composition with weight loss function and its preparation method” has not yet been translated into results.
Hongyuan Pharmaceutical (301246.SZ): The ban on sale of 2.885,500 restricted shares will be lifted on September 20
Glonghui, September 14, 丨 Hongyuan Pharmaceutical (301246.SZ) announced an indicative announcement on the listing and circulation of restricted shares for the initial public offering of offline placement. The total number of shareholders applying to lift sales restrictions was 5,274. The number of restricted shares was 2,885,535 million shares, accounting for 0.72% of the company's total share capital. The sales limit period is 6 months from the date the company's shares were listed; the date for lifting the restricted shares was September 20, 2023 (Wednesday).
Are there any opportunities to make money from IPOs?
All in all, good food is about to come, and the good news in the Hong Kong stock market is yet to come.
Hongyuan Pharmaceutical (301246.SZ) 2022 equity distribution: 1 yuan for every 10 shares, share registration on June 5
According to the Zhitong Finance App, Hongyuan Pharmaceutical (301246.SZ) announced that the company's 2022 equity distribution plan is to distribute 1 yuan in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital. The registration date for this equity distribution is: June 5, 2023, and the deduction date is: June 6, 2023.
Hongyuan Pharmaceutical: Currently, the company has a lithium hexafluorophosphate production capacity of 8,000 tons/year
Gelonghui, May 26 丨 Hongyuan Pharmaceutical recently stated during an investor reception event that the company currently has a production capacity of 8,000 tons/year of lithium hexafluorophosphate. In addition, the participating company, Hubei Zhonglan Hongyuan New Energy Materials Co., Ltd. (the company holds 41% of the shares), has a lithium hexafluorophosphate production capacity of 4,000 tons/year. In the future, the company will continuously enhance the market competitiveness of the company's lithium hexafluorophosphate business through iterative upgrading of technology and expansion upstream into the industrial chain. At the same time, it will form industrial collaboration with the lithium hexafluorophosphate business around the lithium battery electrolyte material layout, and continue to enhance the business scale and market competitiveness of the company's lithium battery sector.
Analysis
Price Target
No Data
